Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess whether the efficacy of ocrelizumab 600 mg intravenously every 24 weeks is superior to Rebif® as measured by the annualized protocol-defined relapse rate by two years in patients with relapsing multiple sclerosis.
Critère d'inclusion
- Relapsing Multiple Sclerosis